Alexar Therapeutics, Inc. is focused on developing an innovative portfolio of Liver X receptor (LXR) agonists.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/02/14 | $21,500,000 | Series A |
New Science Ventures NeXeption Palo Alto Investors Third Point Ventures | undisclosed |
